Status:
ACTIVE_NOT_RECRUITING
Web-Based Exercise for Neuropathy and Quality of Life in Breast Cancer
Lead Sponsor:
Bilecik Seyh Edebali Universitesi
Conditions:
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Breast Cancer
Eligibility:
FEMALE
18-75 years
Phase:
NA
Brief Summary
Chemotherapy is a widely used treatment method for cancer patients. However, various side effects may occur depending on the drug used, treatment duration, and dosage. One of these side effects is che...
Detailed Description
Breast cancer is the most common type of cancer among women worldwide and in our country, ranking second among the leading causes of cancer-related deaths. Chemotherapy drugs are among the most widely...
Eligibility Criteria
Inclusion
- Able to understand and speak Turkish,
- Over 18 years of age,
- Receiving taxane-based chemotherapy in daytime chemotherapy units,
- Reporting at least one neuropathy symptom according to CIPNAT,
- Diagnosed with stage II-III breast cancer,
- Receiving a planned weekly taxane-based chemotherapy infusion dose (70-99 mg/m², 100-129 mg/m², 130-159 mg/m², 160 mg/m² and above) and completing 8 treatment cycles,
- Having internet access,
- No history of deep vein thrombosis,
- Not using anticoagulant medication,
- Willing to participate in the study.
Exclusion
- Younger than 18 years or older than 75 years,
- Having central nervous system disorders affecting movement, balance, sensation, or coordination,
- Presence of any skin infection, scar tissue, inflammation, or incision on the hands or ankles,
- Diagnosed with a proven cardiac condition or using medication for cardiac issues,
- Pregnant women or those in the postpartum period,
- History of polyneuropathy before chemotherapy,
- Cognitive impairment,
- Presence of metal implants in the exposure area,
- History of any other malignancy,
- Undergoing mastectomy.
- Withdrawal Criteria
- Patients meeting the following conditions will be withdrawn from the study:
- Patients whose taxane treatment protocol is changed,
- Patients who wish to withdraw from the study,
- Patients with a pulse rate above 100 bpm,
- Patients receiving fewer than four weekly chemotherapy applications,
- Women without internet access or those who do not visit the website at least five times for four hours throughout the follow-up period.
Key Trial Info
Start Date :
May 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 10 2025
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06879678
Start Date
May 28 2025
End Date
October 10 2025
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gulhane Education and Research Hospital, Ankara, 06010
Ankara, Turkey (Türkiye), 06010